- Home
- OGI vs CHRS Comparison
OGI vs CHRS Comparison
Compare OGI & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGI
- CHRS
- Stock Information
- Founded
- OGI 2013
- CHRS 2010
- Country
- OGI Canada
- CHRS United States
- Employees
- OGI N/A
- CHRS N/A
- Industry
- OGI Biotechnology: Pharmaceutical Preparations
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OGI Health Care
- CHRS Health Care
- Exchange
- OGI Nasdaq
- CHRS Nasdaq
- Market Cap
- OGI 165.0M
- CHRS 185.5M
- IPO Year
- OGI N/A
- CHRS 2014
- Fundamental
- Price
- OGI $1.59
- CHRS $1.67
- Analyst Decision
- OGI
- CHRS Strong Buy
- Analyst Count
- OGI 0
- CHRS 4
- Target Price
- OGI N/A
- CHRS $5.38
- AVG Volume (30 Days)
- OGI 726.1K
- CHRS 10.3M
- Earning Date
- OGI 02-11-2025
- CHRS 11-06-2024
- Dividend Yield
- OGI N/A
- CHRS N/A
- EPS Growth
- OGI N/A
- CHRS N/A
- EPS
- OGI N/A
- CHRS N/A
- Revenue
- OGI $110,297,722.00
- CHRS $304,340,000.00
- Revenue This Year
- OGI $8.76
- CHRS $1.64
- Revenue Next Year
- OGI $14.04
- CHRS $16.98
- P/E Ratio
- OGI N/A
- CHRS N/A
- Revenue Growth
- OGI 2.33
- CHRS 44.19
- 52 Week Low
- OGI $1.21
- CHRS $0.66
- 52 Week High
- OGI $2.91
- CHRS $3.70
- Technical
- Relative Strength Index (RSI)
- OGI 57.86
- CHRS 67.08
- Support Level
- OGI $1.45
- CHRS $1.45
- Resistance Level
- OGI $1.73
- CHRS $1.85
- Average True Range (ATR)
- OGI 0.10
- CHRS 0.22
- MACD
- OGI 0.02
- CHRS 0.01
- Stochastic Oscillator
- OGI 74.19
- CHRS 42.21
About OGI Organigram Holdings Inc.
OrganiGram Holdings Inc is engaged in producing indoor-grown cannabis for patients and adult recreational consumers in Canada. The company has also developed a portfolio of adult-use recreational cannabis brands including Edison, Big Bag o' Buds, SHRED, Monjour, Holy Mountain, and Trailblazer. Tremblant Cannabis, and artisanal craft brand, Laurentian are recent additions to Organigram's existing brand portfolio.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.